Evaluation of tumor burden after sequential molecular-targeted therapy in patients with metastatic renal cell carcinoma
Author:
Affiliation:
1. Department of Urology, Kidney Center, Tokyo Women's Medical University, 8-1 Kawada-cho, Shinjuku-ku, Tokyo162-8666, Japan
Publisher
Oxford University Press (OUP)
Subject
Cancer Research,Radiology, Nuclear Medicine and imaging,Oncology,General Medicine
Link
http://academic.oup.com/jjco/article-pdf/47/3/226/26648772/hyw196.pdf
Reference21 articles.
1. Novel agents and approaches for advanced renal cell carcinoma;Figlin;J Urol,2012
2. Overall survival and updated results for sunitinib compared with interferon alfa in patients with metastatic renal cell carcinoma;Motzer;J Clin Oncol,2009
3. The use of prognostic factors in metastatic renal cell carcinoma;Li;Urol Oncol,2015
4. New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1);Eisenhauer;Eur J Cancer,2009
5. Tumour burden is an independent prognostic factor in metastatic renal cell carcinoma;Iacovelli;BJU Int,2012
Cited by 9 articles. 订阅此论文施引文献 订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献
1. Baseline Tumor Size as Prognostic Index in Patients With Advanced Solid Tumors Receiving Experimental Targeted Agents;The Oncologist;2023-08-07
2. Association of tumor burden with outcome in first-line therapy with nivolumab plus ipilimumab for previously untreated metastatic renal cell carcinoma;Japanese Journal of Clinical Oncology;2021-09-08
3. Responses to Targeted Therapy among Organs Affected by Metastasis in Patients with Renal Cell Carcinoma are Organ-Specific;UROL J;2021
4. Isolated Pancreatic Metastases of Renal Cell Carcinoma—A Paradigm of a Seed and Soil Mechanism: A Literature Analysis of 1,034 Observations;Frontiers in Oncology;2020-05-29
5. Efficacy of immune checkpoint inhibitor monotherapy for patients with massive non-small-cell lung cancer;Journal of Cancer Research and Clinical Oncology;2020-05-27
1.学者识别学者识别
2.学术分析学术分析
3.人才评估人才评估
"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370
www.globalauthorid.com
TOP
Copyright © 2019-2024 北京同舟云网络信息技术有限公司 京公网安备11010802033243号 京ICP备18003416号-3